About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

NCT04857827·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Qlaris Bio, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Visual acuity +1.0 logMAR or better
2. Willing to give informed consent
3. Ability to washout from current intraocular pressure lowering medications -

You may not be if

1. All secondary glaucomas
2. Previous glaucoma intraocular or laser surgery (selective laser trabeculoplasty permitted when done 18 months or longer from Screening)
3. Refractive surgery
4. Ocular infection or inflammation

The record

StatusCompleted

PhasePhase 2

Taking part30

StartedSep 2021

UpdatedJan 20, 2025

Conditions

Normal Tension Glaucoma (NTG)

Where1

Vance Thompson Vision
Sioux Falls, South Dakota, United States

Clareo Health | A Study to Evaluate Safety and Tolerability of QLS-101 in NTG